Lyell Immunopharma Announces That Two Abstracts Featuring Updated Clinical Data For Rondecabtagene Autoleucel Have Been Accepted To The American Society Of Hematology Meeting, December 12–15; Ronde-Cel Achieved 91% Overall Response Rate And 77% Complete Response Rate

Loading news article.

Lyell Immunopharma Announces That Two Abstracts Featuring Updated Clinical Data For Rondecabtagene Autoleucel Have Been Accepted To The American Society Of Hematology Meeting, December 12–15; Ronde-Cel Achieved 91% Overall Response Rate And 77% Complete Response Rate | WAPE

Lyell Immunopharma Announces That Two Abstracts Featuring Updated Clinical Data For Rondecabtagene Autoleucel Have Been Accepted To The American Society Of Hematology Meeting, December 12–15; Ronde-Cel Achieved 91% Overall Response Rate And 77% Complete Response Rate

Article summary

Related companies

Analyzed by WAPE AI.

Comments —